Translational analysis and final efficacy of the AVETUX trial–Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
J Tintelnot, I Ristow, M Sauer, D Simnica… - Frontiers in …, 2022 - frontiersin.org
… Most tumors of patients suffering from metastatic colorectal cancer (mCRC) are microsatellite
stable (MSS) tumors (1). However, the efficacy of immunotherapies such as immune …
stable (MSS) tumors (1). However, the efficacy of immunotherapies such as immune …
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS …
S Napolitano, G Martini, D Ciardiello, M Di Maio… - Frontiers in …, 2022 - frontiersin.org
… has limited efficacy in metastatic colorectal cancer (mCRC). … and centrally stored for
additional translational studies. … -arm, multi-center phase II study of cetuximab plus avelumab as …
additional translational studies. … -arm, multi-center phase II study of cetuximab plus avelumab as …
Translational research of new developments in targeted therapy of colorectal cancer
L Yang, N Atakhanova, MTC Arellano… - Pathology-Research …, 2023 - Elsevier
… tumor cells into the colon and rectum wall, leading to stage 2. … with Cetuximab adagrasib
exhibited anti-tumor activity in … treatment and had metastatic colorectal cancer with mutant KRAS …
exhibited anti-tumor activity in … treatment and had metastatic colorectal cancer with mutant KRAS …
Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial
E Martinelli, G Martini, V Famiglietti, T Troiani… - JAMA …, 2021 - jamanetwork.com
… , single arm, multicenter phase 2 study of cetuximab plus avelumab as rechallenge treatment
… Translational and functional studies are needed to understand the potential additive and/or …
… Translational and functional studies are needed to understand the potential additive and/or …
… methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC …
K Ouchi, S Takahashi, K Sasaki, Y Yoshida… - … Journal of Colorectal …, 2024 - Springer
… of cetuximab to irinotecan as a second-line treatment for mCRC would contribute to prolonged
survival [9]. The objective of this translational research … with metastatic colorectal cancer. …
survival [9]. The objective of this translational research … with metastatic colorectal cancer. …
Maintenance therapy with cetuximab after FOLFIRI plus cetuximab for RAS wild-type metastatic colorectal cancer: A phase 2 randomized clinical trial
V Boige, H Blons, E François, MB Abdelghani… - JAMA Network …, 2023 - jamanetwork.com
… or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal
cancer: phase II randomised MACRO2 TTD study. …
cancer: phase II randomised MACRO2 TTD study. …
Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
AR Parikh, E Gonzalez-Gugel, N Smolyakova… - The …, 2022 - academic.oup.com
… Five phase 2 studies with cetuximab Q2W/Q1W … cetuximab is efficacious and safe as
monotherapy or in combination with chemotherapy for patients with metastatic colorectal cancer (…
monotherapy or in combination with chemotherapy for patients with metastatic colorectal cancer (…
[HTML][HTML] Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of …
S Takahashi, K Ouchi, Y Sakamoto, T Mori… - Journal of …, 2023 - ncbi.nlm.nih.gov
… the translational research of TRICOLORE, randomized phase III … this study were that it was
a Japanese, single-arm, phase II … Therefore, in some analyses, the study was underpowered, …
a Japanese, single-arm, phase II … Therefore, in some analyses, the study was underpowered, …
… plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
E Martinelli, G Martini, T Troiani… - Annals of …, 2020 - annalsofoncology.org
… arm multi-centre phase II study, aims to evaluate the efficacy of avelumab and cetuximab in
… This study seeks to demonstrate a mOS of 11 months (mo) for the experimental combination …
… This study seeks to demonstrate a mOS of 11 months (mo) for the experimental combination …
… for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial
C Cremolini, D Rossini, E Dell'Aquila, S Lonardi… - JAMA …, 2019 - jamanetwork.com
… Design, Setting, and Participants Multicenter phase 2 single-arm trial conducted from …
preliminary evidence, supported by a sound translational background, to be further confirmed in a …
preliminary evidence, supported by a sound translational background, to be further confirmed in a …